Given that decreased plasma adiponectin levels have also been implicated in other diseases, e.g., cardiovascular diseases (32, 33), cancer (34), scleroderma (35), and endometriosis (36), the indications for AdipoRaMab are expected to extend beyond diabetes and NASH. This evidence concerns the gene ADIPOQ and cancer.